http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-3032146-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_627acf3b3095acb9831b527825a6ba5f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 |
| filingDate | 2017-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1651d8cf989fff246af1f8c11055871 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0eabc57faaabeeb290d27eca251b270d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6428cde3bf97114d98a8a7ea5dc6965 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e06dbde8318dae4109950af17a1c9f7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_baabdfc80e818ae2585e2c4a535019ab |
| publicationDate | 2018-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-3032146-A1 |
| titleOfInvention | Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy |
| abstract | The ligand for VISTA is identified (VSIG3) as well as the use of this ligand and receptor interaction in the identification or synthesis of a VSIG3 agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of VSIG3 and/or VISTA and/or the VSIG3/VISTA interaction. These antagonists may be used to suppress VSIG/3/VISTA's suppressive effects on T cell immunity, and more particularly used in the treatment of cancer, or infectious disease. These agonist compounds may be used to potentiate or enhance VSIG3/VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity, such as in the treatment of autoimmunity, allergy or inflammatory conditions. Screening assays for identifying these agonists and antagonist compounds are also provided. |
| priorityDate | 2016-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1871.